Author Archives: admin


Stem Cell Clinic > Articles by: admin

Longevity And Anti-Senescence Therapy Market Value Chain and Forecast COVID-19 2023 – Kentucky Journal 24

By Stem Cell Treatment

The global longevity and anti-senescence therapies market should grow from $329.8 million in 2018 to $644.4 million by 2023 with a compound annual growth rate (CAGR) of 14.3% during 2018-2023.

Report Scope:

The scope of this report is broad and covers various therapies currently under trials in the global longevity and anti-senescence therapy market. The market estimation has been performed with consideration for revenue generation in the forecast years 2018-2023 after the expected availability of products in the market by 2023. The global longevity and anti-senescence therapy market has been segmented by the following therapies: Senolytic drug therapy, Gene therapy, Immunotherapy and Other therapies which includes stem cell-based therapies, etc.

Request for Report Sample:https://www.trendsmarketresearch.com/report/sample/11698

Revenue forecasts from 2028 to 2023 are given for each therapy and application, with estimated values derived from the expected revenue generation in the first year of launch.

The report also includes a discussion of the major players performing research or the potential players across each regional longevity and anti-senescence therapy market. Further, it explains the major drivers and regional dynamics of the global longevity and anti-senescence therapy market and current trends within the industry.

The report concludes with a special focus on the vendor landscape and includes detailed profiles of the major vendors and potential entrants in the global longevity and anti-senescence therapy market.

Report Includes:

71 data tables and 40 additional tables An overview of the global longevity and anti-senescence therapy market Analyses of global market trends, with data from 2017 and 2018, and projections of compound annual growth rates (CAGRs) through 2023 Country specific data and analysis for the United States, Canada, Japan, China, India, U.K., France, Germany, Spain, Australia, Middle East and Africa Detailed description of various anti-senescence therapies, such as senolytic drug therapy, gene therapy, immunotherapy and other stem cell therapies, and their influence in slowing down aging or reverse aging process Coverage of various therapeutic drugs, devices and technologies and information on compounds used for the development of anti-ageing therapeutics A look at the clinical trials and expected launch of anti-senescence products Detailed profiles of the market leading companies and potential entrants in the global longevity and anti-senescence therapy market, including AgeX Therapeutics, CohBar Inc., PowerVision Inc., T.A. Sciences and Unity Biotechnology

Summary

Global longevity and anti-senescence therapy market deals in the adoption of different therapies and treatment options used to extend human longevity and lifespan. Human longevity is typically used to describe the length of an individuals lifetime and is sometimes used as a synonym for life expectancy in the demography. Anti-senescence is the process by which cells stop dividing irreversibly and enter a stage of permanent growth arrest, eliminating cell death. Anti-senescence therapy is used in the treatment of senescence induced through unrepaired DNA damage or other cellular stresses.

Global longevity and anti-senescence market will witness rapid growth over the forecast period (2018-2023) owing to an increasing emphasis on Stem Cell Research and an increasing demand for cell-based assays in research and development.

An increasing geriatric population across the globe and a rising awareness of antiaging products among generation Y and later generations are the major factors expected to promote the growth of global longevity and anti-senescence market. Factors such as a surging level of disposable income and increasing advancements in anti-senescence technologies are also providing traction to the global longevity and anti-senescence market growth over the forecast period (2018-2023).

According to the National Institutes of Health (NIH), the total geriatric population across the globe in 2016 was over REDACTED. By 2022, the global geriatric population (65 years and above) is anticipated to reach over REDACTED. An increasing geriatric population across the globe will generate huge growth prospectus to the market.

Senolytics, placenta stem cells and blood transfusions are some of the hot technologies picking up pace in the longevity and anti-anti-senescence market. Companies and start-ups across the globe such as Unity Biotechnology, Human Longevity Inc., Calico Life Sciences, Acorda Therapeutics, etc. are working extensively in this field for the extension of human longevity by focusing on study of genomics, microbiome, bioinformatics and stem cell therapies, etc. These factors are poised to drive market growth over the forecast period.

Global longevity and anti-senescence market is projected to rise at a CAGR of REDACTED during the forecast period of 2018 through 2023. In 2023, total revenues are expected to reach REDACTED, registering REDACTED in growth from REDACTED in 2018.

The report provides analysis based on each market segment including therapies and application. The therapies segment is further sub-segmented into Senolytic drug therapy, Gene therapy, Immunotherapy and Others. Senolytic drug therapy held the largest market revenue share of REDACTED in 2017. By 2023, total revenue from senolytic drug therapy is expected to reach REDACTED. Gene therapy segment is estimated to rise at the highest CAGR of REDACTED till 2023. The fastest growth of the gene therapy segment is due to the Large investments in genomics. For Instance; The National Human Genome Research Institute (U.S.) had a budget grant of REDACTED for REDACTED research projects in 2015, thus increasing funding to REDACTED for approximately REDACTED projects in 2016.

More Info of Impact Covid19@https://www.trendsmarketresearch.com/report/covid-19-analysis/11698

View post:
Longevity And Anti-Senescence Therapy Market Value Chain and Forecast COVID-19 2023 - Kentucky Journal 24

New coronavirus treatments are expected this fall. But how powerful will they be? – Toronto Star

By Stem Cell Treatment

WASHINGTONThe Trump administration is hoping that a sophisticated new drug treatment to prevent people from getting severely ill from COVID-19 will be available to the public by this fall.

But experts in the field say that treatments most likely to reach the market in September or October are more modest, repurposed therapeutic drugs meant to treat late-stage symptoms of the illness.

Hundreds of treatments and antivirals are currently undergoing U.S. clinical trials. But the potential drugs that are furthest along in the process are medications already on the market to treat other illnesses or have been under review for many years.

Many of those are anti-inflammatory and blood clot treatments that could mitigate the severity of the disease, decrease hospital stays and reduce fatalities.

The success of these more modest drugs would be less dramatic than a tailor-made treatment that could prevent the disease from progressing to a life-threatening state. But they could still alter the dynamics of an expected autumn wave of the coronavirus pandemic in the United States, which already has taken over 138,000 lives and continues to ripple across the country.

If you look at the pipeline, there are more shots on goal on the treatment side the late-stage inflammatory issues, said David Thomas, vice-president of industry research at BIO, a major trade association representing biotechnology companies and institutions. The goal would be to have more therapeutics that would decrease the severity of the late-stage disease.

The hope is that these drugs might help lower the death toll and the burden on intensive care units in hospitals.

Experts compare the impact of these drugs to that of remdesivir, the most prominent repurposed, antiviral treatment currently available to coronavirus patients. The drug is produced by Gilead Sciences and was originally tested for its effectiveness against other infectious diseases, including the SARS and MERS coronaviruses.

Preliminary clinical trials on the effects of remdesivir in coronavirus patients found that the drug has reduced hospitalization times. More robust clinical trials will be necessary to determine the extent to which the drug helps patients recover.

You have this emergent need for therapeutics, and people are taking everything they have off the shelf, said Dr. Lawrence Blatt, chief executive officer of Aligos Therapeutics, a California-based biotechnology company currently working on a therapeutic candidate for COVID-19. The net result is that most of the therapeutics that are in clinical trials right now are either not going to be effective or will have marginal benefit.

Lets think of it like a lock and key. Each virus has its own lock, Blatt continued. If you took your key from one door and tried to unlock another door, it wouldnt work very well. You have to make a key for that door specifically.

Experimental drug cocktail

A specific key is the gold standard for a coronavirus treatment, and is the current goal of the federal government, which this month placed a $450-million US bet on an experimental drug cocktail that could help infected individuals beat back the coronavirus at earlier stages of infection or even prevent infection in the first place.

We are investing in the candidates that are furthest along so that we could have products by early fall of 2020, a senior administration official working on Operation Warp Speed, the government program to expedite the discovery and production of a coronavirus vaccine, said referring to therapeutics.

While we think it is fair to say that vaccine progress is occurring at warp speed pace, faster than any vaccine has been developed in history, therapeutics are even faster, and we believe well have new options for saving American lives as soon as the early fall, the official told reporters last week.

The drug cocktail, produced by Regeneron, is being made from scratch to address the coronavirus using what is known as monoclonal antibodies protective proteins that have been identified by lab scientists and produced on a large scale to fight off the virus.

It is unclear whether the project will succeed Regeneron has pulled another monoclonal antibody treatment designed to treat rheumatoid arthritis from consideration as a COVID-19 treatment. If the new drug cocktail works, only 300,000 doses will be available by the end of autumn, far short of expected demand.

That would leave doctors and nurses still largely relying on the other repurposed, late-stage treatments, even if Regenerons product ultimately proves successful.

We know that vaccines will take a while, so theres been a lot of discussion about using different kinds of drugs some old drugs, said David Eller, the chairman, co-founder and chief executive officer of Celltex Therapeutics, a Texas-based biotech company conducting Phase II clinical trials for a stem cell treatment of COVID-19. The real issue is, we need something today.

Still, the less ambitious, late-stage treatments that have shown promise could blunt two of the main phenomena identified, up to this point, as fatal to severely ill COVID-19 patients: hyperinflammation and blood clotting.

The lung only fails in so many different ways, and it doesnt matter if its SARS CoV-2, or influenza, or metapneumovirus, said Richard Boucher, director of the Marsico Lung Institute at the University of North Carolina School of Medicine, explaining why he believes some repurposed drugs currently under consideration to treat COVID-19 patients could work. Its going to be therapies that are going to be useful, but are going to be incremental.

Mitigating contagiousness

Last month, Boucher released a major study on how the coronavirus primarily infects the respiratory tract through the nose a critical finding in the search for therapeutics.

Treatments that attempt to mobilize the power of the immune system are proving far more complicated to achieve, Boucher said.

Never miss the latest news from the Star, including up-to-date coronavirus coverage, with our email newsletters

Theres no question that antivirals would be better if you can get them in early, he said. But the second half of the disease, which is immune mediated, is going to be complex. Its a delicate balance. I mean, were on a knifes edge all the time immunologically.

Some scientists are hopeful that the chances of achieving a simpler, early-stage treatment will increase the more they learn about the nature of the coronavirus.

In Miami-Dade County in Florida, Dr. Gustavo Ferrer, president of the Aventura Pulmonary Institute, is working on a therapeutic method recently submitted to the Food and Drug Administration for review that might diminish the viral load of a new infection using a simple nasal spray.

Addressing the potency of the virus early on in the infection would prevent the disease from progressing to a serious stage, and could help mitigate its contagiousness, Ferrer said.

Pharmaceutical companies, he said, are focusing on treating people who have moderate to severe disease.

The great majority of people have mild to moderate symptoms and never get to respiratory failure, Ferrer added. But those people are the ones passing the virus, and were not using anything to control the viral load in that group other than using masks and social distancing.

Blood donations of recovered patients

Five months since the coronavirus outbreak became apparent nationwide, only a handful of treatments have been authorized by the FDA for emergency use on severely ill patients.

The Trump administrations focus remains on monoclonal antibody drugs as well as treatment methods that harness antibodies from the blood donations of recently recovered coronavirus patients convalescent plasma and hyperimmune globulin treatments.

Dr. Janet Woodcock, director of the FDAs Center for Drug Evaluation and Research, is leading the agencys effort to identify therapeutic drugs for the coronavirus. She told reporters last week that the government has been unable to stockpile convalescent plasma because donations are being used up in the current wave of cases across the southern states.

We are in the midst of an outbreak at the moment, said Woodcock. Were doing everything we can to make it available.

Without a strategic supply of convalescent plasma and a massive stockpile of FDA-approved monoclonal antibody drugs to meet demand, the best hope for the fall might well be more modest drugs that can slow down the death rate, experts say.

Over 286 treatments, 192 antiviral drugs and 169 vaccines are currently undergoing clinical trials in the United States, according to a BIO database of coronavirus therapeutic development.

White House press secretary Kayleigh McEnany said last week that therapeutics already in use like remdesivir and convalescent plasma are examples of successes in the U.S. response to the pandemic.

President Donald Trump, at a press conference on Tuesday, said that more therapeutics would hopefully be distributed in the near future.

People are feeling good about our country, Trump said. People are feeling good about therapeutics and possible vaccines.

Report an error

Journalistic Standards

About The Star

Read the original post:
New coronavirus treatments are expected this fall. But how powerful will they be? - Toronto Star

Cancer And Your Self-Image: Adjusting Is an Ongoing Process – Curetoday.com

By Stem Cell Treatment

Cancer changes everything about ones self-image, but that doesnt mean it is a negative outcome.

As cancer treatment begins, a persons body may begin to look and feel different, which can impact self-image and sense of self. Treatments can also bring physical scars, hair loss, weight changes, loss of limbs or organs, the need for an ostomy, reduced fertility or other changes, all of which impact a persons physical relationship with their body and have lasting social and emotional impacts.

CANCER ALTERS SENSE OF SELF

Because sense of self plays a significant role in how we interact with the world and relate to others, people who experience physical changes as a result of cancer may not feel comfortable doing things they wouldnt have given a second thought to before, such as meeting new people or going out in public. For those whove experienced physical changes, its important to talk about these feelings, understand that theyre normal and recognize that it takes time to emotionally adjust to the new physical realities.

Managing emotional concerns related to self-image is an ongoing process. People with cancer must acknowledge what happened to them and how it affects their day to day. This requires navigating a sense of emotional and physical loss and confronting how they see them- selves and how they think the world may see them too. In an episode of Cancer Out Loud: The CancerCare Podcast, Bianca, a cancer survivor, said, It doesnt matter the age, just the idea that you are removing your entire breast. I lost everything. ... You dont feel beautiful. Bianca later related living with physical changes like hair loss to playing a role as an actress: Im saying to myself, This is a part, and Im playing this part until I finish chemo. Im beautiful in my own way.

FINDING SUPPORT AND STRENGTH AFTER CANCER

Because physical changes can be reminders of the disease and its treatments, they can be difficult to reconcile with how someone previously viewed themselves. Individual counseling can help survivors process the uniquely personal impact of cancer and transition to a new physical reality by offering a safe, supportive and uncensored environment to express thoughts and feelings.

Oncology social workers, counselors, therapists or supportive professionals may be able to share strategies for practicing mindfulness, self-care and kindness amidst this emotionally turbulent experience. Additionally, joining a support group and connecting with people facing similar challenges can also help lessen feelings of loneliness and isolation. As much as friends and family want to understand, they often cant relate. Support groups are a place where survivors can express their fears, feelings and experiences with other people who truly understand because theyre living with cancer, too.

Although physical changes can serve as reminders of negative and painful memories, they can also be symbols of strength.

When you are pale yellow and your skin is totally different, its harder to feel beautiful, said Bianca. (Cancer helped me realize that) its all (about) the heart. I feel beautiful in a different way. Its not the outside beauty. The beauty is inside us and now Im a strong believer of this.

Original post:
Cancer And Your Self-Image: Adjusting Is an Ongoing Process - Curetoday.com

Living Well: PRP: A Promising Treatment – The Daily Progress

By Platelet Rich Plasma Injections

While its not considered to be a miracle cure, platelet-rich plasma (PRP) has emerged in recent years as a useful new treatment option for some patients. Injecting PRP into certain inflamed or damaged areas of the body can help relieve pain and, in some cases, may enhance the bodys natural healing processes to help speed up recovery.

Undergoing a PRP treatment is fairly simple. All thats involved is a consultation, a blood draw and an injection. This often can be done in the same office visit.

Platelets are the blood cells that help the body control bleeding by forming clots, but platelets also naturally contain a huge amount of growth factors, which can act as healing agents. When those growth factors are injected into damaged structures, they can activate and enhance the bodys natural healing process.

PRP injection is especially effective in cases of inflammatory tendinitis, such as Achilles tendinitis, tennis elbow, and tendinitis of the rotator cuff and knee, according to Matthew Panzarella, MD, with the Sentara Sports Medicine Center.

PRP is a therapy we may consider if other conservative treatmentssuch as rest, physical therapy and icing, for examplehave proven ineffective, he says. Theres a lot of good data showing that PRP helps with inflammatory tendon problems, and in some cases it can help a patient delay or even avoid surgery.

In addition to healing tendons, the FDA-approved PRP technique can be used in certain cases to help heal damaged muscles and ligaments, and it can help relieve pain associated with cartilage tears and arthritis.

Superconcentrated Healing Platelets

The key to how PRP works lies in superconcentration of the platelets. As part of the treatment, about 15 milliliters (approximately 1 fluid ounce) of the patients blood is taken from the arm. The blood sample is then put in a centrifuge and spun down to separate the platelets from the plasma. The spinning process superconcentrates the platelets, which are then injected into the injured area of the patients body.

Physicians like Dr. Panzarella inject the PRP into the target site with the assistance of ultrasound guidance, which permits them to see exactly where the needle is being placed. The use of ultrasound guidance helps to ensure that the platelets are going directly into the damaged area where theyre most needed.

What Platelet-Enriched Plasma Canand CannotDo

Dr. Panzarella notes that patients often ask if PRP can help regrow or regenerate torn or arthritic cartilage.

The answer is no, he says. Even though platelets have growth factors, they wont regrow damaged or torn cartilage. But PRP therapy can still help with reduction of pain and inflammation in cases of torn and damaged cartilage. Platelets have a natural anti-inflammatory property, and PRP can help reduce inflammation and its associated pain in many cases of arthritis, torn meniscus and similar cartilage problems.

In cases where PRP seems to have a direct healing effect on structures like torn tendons and torn ligaments, the effect is dependent on the extent of injury.

Who is a Candidate for PRP?

Dr. Panzarella considers a number of criteria in helping patients decide whether PRP is right for them. These criteria include the extent type and location of the injury, and in the case of arthritis, the level of severity. A patients medication list also can factor into whether they are a candidate for PRP. This discussion takes place during an initial office visit, when treatment options, including PRP, are considered.

If the patient is a good candidate, the next step is typically to schedule an MRI (magnetic resonance imaging) scan to determine the extent and precise nature of the patients problem. If the patient decides to go forward with PRP therapy, an outpatient office visit is scheduled, during which the patients blood will be taken and spun down to concentrate the platelets, and then the patient will receive the injection.

After the injection, patients follow up with their physician in a few weeks, and frequently are referred to rehabilitation, if appropriate.

Are There Any Risks Associated with PRP?

PRP injections involve little risk because the patient is receiving his or her own blood product, so there is no concern with mismatched blood typing, transmission of disease or risk of rejection.

Anytime you stick a needle under the skin, theres a risk of infection, says Dr. Panzarella. But that risk is very lowwe clean the injection site really well.

Probably the biggest risk with PRP is that the treatment may not work. Dr. Panzarella points out to his patients that there are no guarantees with PRP, and insurance does not currently cover the cost of the procedure.

To help ensure that their patients have the best outcome possible with PRP, physicians have some recommendations for their patients.

I ask patients not to take any anti-inflammatory medications like ibuprofen, naproxen or meloxicam for 48 hours before their injection, and for a week afterwards, says Dr. Panzarella. Certain chemicals in nonsteroidal anti-inflammatory drugs like these can inhibit the release of healing elements from the platelets.

If you think you might benefit from PRP or have a sports related injury and need an appointment, call the Sentara Sports Medicine Center at 434-654-5575.

Originally posted here:
Living Well: PRP: A Promising Treatment - The Daily Progress

Cell Culture Media Market with (Covid-19) Impact Analysis: In-depth Analysis, Global Market Share, Top Trends, Professional & Technical Industry…

By Stem Cell Medicine

Zion Market Research,A leading market research firm added a research report onCell Culture Media Market; by Reagent Type (Albumin, Hormones, Attachment Factors, Amino acid, and Growth factors and Cytokines); by Type (Chemically-defined media, Classical media, Lysogeny broth, Protein-free media, Serum-free media, and Specialty media); for Applications (Biopharmaceuticals and Therapeutics, Biotech Research, Cancer, Drug Screening and Drug Development, Regenerative Medicine and Tissue Engineering, and Stem Cell Technologies); and by End-users (Biotechnology and Pharmaceutical companies, Research Laboratories, Academic Institutes, and Pathology Labs): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 2026to its research database. This Cell Culture Media Market report analyzes the comprehensive overview of the market comprising an executive summary that covers core trends evolving in the market.

TheCell Culture Media marketreport aims to provide a powerful resource to evaluate the Cell Culture Media market and comprises comprehensive scrutiny and straightforward statistics relating to the market. The report offers knowledgeable information to the clients enhancing their decision-making capability with regards to the Cell Culture Media market business. The report entails the major leading market players around the world with insights such as market share, product pictures & specifications, sales, company profiles, and contact details.

Request Free Sample Copy of Cell Culture Media Market Research Report @https://www.zionmarketresearch.com/sample/cell-culture-media-market

(The sample of this report is readily available on request).

This Free report sample includes:

Furthermore, the report provides the explored data by categorizing the Cell Culture Media market based on type and form of service or product, applications, the technology involved, end-users, and others. It also entails comprehensive data relating to particular financial and business terms, anticipated market growth, market strategies, and much more. Using graphs, flowcharts, and figures in the report, the professional presented the examined information in a better comprehensible manner.

Additionally, the report also encompasses an explanation of key factors that are likely to considerably stimulate or hamper Cell Culture Mediamarket growth. It also elucidates on the future impact of enforcing regulations and policies on Cell Culture Mediamarket growth. The computed expected CAGR of the Cell Culture Media market based on earlier records about the Cell Culture Media market and existing market trends together with future developments are also mentioned in the report. The report also comprises the geographical bifurcation of the Cell Culture Media market.

Download Free PDF Report Brochure @https://www.zionmarketresearch.com/requestbrochure/cell-culture-media-market

(You may enquire a report quote OR available discount offers to our sales team before purchase.)

Some of Major Market Player ProfilesIncluded in this Report Are:

Analytical Biological Services Inc., Atlanta BiologicalsInc., BD Biosciences, Cell EssentialsInc., ClonTech LaboratoriesInc., GE Healthcare, JR ScientificInc., Life Technologies, Lonza Bioscience, Merck Millipore, MP Biomedicals, Novozymes Biopharma US In123

The Cell Culture Media Market report provides objective, evenhanded evaluation, and assessment of opportunities in the Cell Culture Media market with a methodical market research report including numerous other market-associated fundamental factors. Our experienced industry analysts estimate the growth opportunities, cost, market sizing, technologies, applications, supply chains, companies, import & export, market share, and so on, with the exclusive endeavor of helping our customers to make well-informed business decisions.

The market beat is reveled in this report which can allow the consumer in using key strategies to gain competitive advantage. Such a far-reaching and thorough research survey gives the essential expansion with key suggestions and unbiased measurable analysis, which can be used to enhance the current position and develop future extensions in a specific area in the Cell Culture Mediamarket.

(We customize your report according to your research need. Ask our sales team for report customization).Imperative regions all over the world are secured and the advancements, patterns, restrictions, drivers, and difficulties impacting the growth of the Cell Culture Mediamarket over these essential areas are covered. An examination of the impact of holistic and government policies on the market is likewise comprised to offer an all-encompassing summary of the future viewpoint of the Cell Culture Media market.

Request Report TOC (Table of Contents) @https://www.zionmarketresearch.com/toc/cell-culture-media-market

The major region covered in this report:

The Middle East and Africa

Inquire more about this report @https://www.zionmarketresearch.com/inquiry/cell-culture-media-market

Some of the major objectives of this report:

1) To provide a detailed analysis of the market structure along with the forecast of the various segments and sub-segments of the global Cell Culture Media market.

2. To provide insights about factors affecting market growth. To analyze the Cell Culture Media market based on various factors- price analysis, supply chain analysis, porter five force analyses, etc.

3. To provide historically and forecast revenue of the Cell Culture Media market segments and sub-segments with respect to four main geographies and their countries- North America, Europe, Asia, and the Rest of the World.

4. Country-level analysis of the market with respect to the current market size and future prospective.

5. To provide country-level analysis of the market for segment by application, product type and sub-segments.

6. To provide strategic profiling of key players in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market.

7. Track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global Cell Culture Media market.

For Urgent Enquiry, Mail Us At:[emailprotected]

About Us:

Zion Market Researchis an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the clients needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to usafter allif you do well, a little of the light shines on us.

Contact Us:

Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States

Tel: +49-322 210 92714 USA/Canada Toll Free No.1-855-465-4651

Email:[emailprotected]

See original here:
Cell Culture Media Market with (Covid-19) Impact Analysis: In-depth Analysis, Global Market Share, Top Trends, Professional & Technical Industry...

Tag: Stem Cell Therapy Europe – Cole of Duty

By Stem Cell Treatment

Takeda (TiGenix)

Scope of the Stem Cell Therapy Market Report:

In the last several years, global stem cell therapy market developed fast at a average growth rate of 46.81%. In 2017, the global stem cell therapy market size was 235 million USD, and the market is expected to be 277 million USD.

On the basis of therapeutic application, the global stem cell therapy market is segmented into Musculoskeletal Disorder, Wounds & Injuries, Cornea, Cardiovascular Diseases, and other applications. The musculoskeletal disorders and Wounds & Injuries are expected to dominated the market.

The global Stem Cell Therapy market is valued at 280 million USD in 2018 and is expected to reach 710 million USD by the end of 2024, growing at a CAGR of 20.7% between 2019 and 2024.

The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.

North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Stem Cell Therapy.

Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.

This report studies the Stem Cell Therapy market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Stem Cell Therapy market by product type and applications/end industries.

Get a Sample Copy of the Stem Cell Therapy Market Report 2020

Report further studies the market development status and future Stem Cell Therapy Market trend across the world. Also, it splits Stem Cell Therapy market Segmentation by Type and by Applications to fully and deeply research and reveal market profile and prospects.

Major Classifications are as follows:

Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth Rate of Stem Cell Therapy in these regions, from 2014 to 2024, covering

This Stem Cell Therapy Market Research/Analysis Report Contains Answers to your following Questions

Inquire more and share questions if any before the purchase on this report at https://www.360researchreports.com/enquiry/pre-order-enquiry/13851136

Major Points from Table of Contents:

1. Market Overview 1.1 Stem Cell Therapy Introduction 1.2 Market Analysis by Type 1.3 Market Analysis by Applications 1.4 Market Dynamics 1.4.1 Market Opportunities 1.4.2 Market Risk 1.4.3 Market Driving Force

2.Manufacturers Profiles

2.4.1 Business Overview 2.4.2 Stem Cell Therapy Type and Applications 2.4.2.1 Product A 2.4.2.2 Product B

3.Global Stem Cell Therapy Sales, Revenue, Market Share and Competition By Manufacturer (2019-2020)

3.1 Global Stem Cell Therapy Sales and Market Share by Manufacturer (2019-2020) 3.2 Global Stem Cell Therapy Revenue and Market Share by Manufacturer (2019-2020) 3.3 Market Concentration Rates 3.3.1 Top 3 Stem Cell Therapy Manufacturer Market Share in 2020 3.3.2 Top 6 Stem Cell Therapy Manufacturer Market Share in 2020 3.4 Market Competition Trend

4.Global Stem Cell Therapy Market Analysis by Regions

4.1 Global Stem Cell Therapy Sales, Revenue and Market Share by Regions 4.1.1 Global Stem Cell Therapy Sales and Market Share by Regions (2014-2019) 4.1.2 Global Stem Cell Therapy Revenue and Market Share by Regions (2014-2019) 4.2 North America Stem Cell Therapy Sales and Growth Rate (2014-2019) 4.3 Europe Stem Cell Therapy Sales and Growth Rate (2014-2019) 4.4 Asia-Pacific Stem Cell Therapy Sales and Growth Rate (2014-2019) 4.6 South America Stem Cell Therapy Sales and Growth Rate (2014-2019) 4.6 Middle East and Africa Stem Cell Therapy Sales and Growth Rate (2014-2019)

5.Stem Cell Therapy Market Forecast (2020-2024) 5.1 Global Stem Cell Therapy Sales, Revenue and Growth Rate (2020-2024) 5.2 Stem Cell Therapy Market Forecast by Regions (2020-2024) 5.3 Stem Cell Therapy Market Forecast by Type (2020-2024) 5.3.1 Global Stem Cell Therapy Sales Forecast by Type (2020-2024) 5.3.2 Global Stem Cell Therapy Market Share Forecast by Type (2020-2024) 5.4 Stem Cell Therapy Market Forecast by Application (2020-2024) 5.4.1 Global Stem Cell Therapy Sales Forecast by Application (2020-2024) 5.4.2 Global Stem Cell Therapy Market Share Forecast by Application (2020-2024)

6.Sales Channel, Distributors, Traders and Dealers 6.1 Sales Channel 6.1.1 Direct Marketing 6.1.2 Indirect Marketing 6.1.3 Marketing Channel Future Trend 6.2 Distributors, Traders and Dealers

7.Research Findings and Conclusion

8.Appendix 8.1 Methodology 8.2 Data Source

Continued..

Purchase this report (Price3480 USD for a single-user license) https://www.360researchreports.com/purchase/13851136

About Us:

360 Research Reports is the credible source for gaining the market reports that will provide you with the lead your business needs. At 360 Research Reports, our objective is providing a platform for many top-notch market research firms worldwide to publish their research reports, as well as helping the decision makers in finding most suitable market research solutions under one roof. Our aim is to provide the best solution that matches the exact customer requirements. This drives us to provide you with custom or syndicated research reports.

Contact Us: Name: Mr. Ajay More Email: [emailprotected] Organization: 360 Research Reports Phone: +44 20 3239 8187/ +14242530807

For More Related Reports Click Here :

Macroscopic Imaging Systems Market 2020 with Covid 19 Impact Analysis includes Top Countries Data, Defination, Market Size, SWOT Analysis, Business Opportunity, Applications, Trends and Forecast to 2026

Hemostasis Diagnostic Analyzers Market 2020 with Covid 19 Impact Analysis includes Top Countries Data, Defination, Market Size, SWOT Analysis, Business Opportunity, Applications, Trends and Forecast to 2026

Myoelectric Prosthetics Market 2020 : Top Countries Data, Defination, Market Size, Detailed Analysis of Current Industry Figures with Forecasts Growth By 2026

Read the rest here:
Tag: Stem Cell Therapy Europe - Cole of Duty

New coronavirus treatments are expected this fall. But how powerful will they be? – TheSpec.com

By Stem Cell Treatment

WASHINGTONThe Trump administration is hoping that a sophisticated new drug treatment to prevent people from getting severely ill from COVID-19 will be available to the public by this fall.

But experts in the field say that treatments most likely to reach the market in September or October are more modest, repurposed therapeutic drugs meant to treat late-stage symptoms of the illness.

Hundreds of treatments and antivirals are currently undergoing U.S. clinical trials. But the potential drugs that are furthest along in the process are medications already on the market to treat other illnesses or have been under review for many years.

Many of those are anti-inflammatory and blood clot treatments that could mitigate the severity of the disease, decrease hospital stays and reduce fatalities.

The success of these more modest drugs would be less dramatic than a tailor-made treatment that could prevent the disease from progressing to a life-threatening state. But they could still alter the dynamics of an expected autumn wave of the coronavirus pandemic in the United States, which already has taken over 138,000 lives and continues to ripple across the country.

If you look at the pipeline, there are more shots on goal on the treatment side the late-stage inflammatory issues, said David Thomas, vice-president of industry research at BIO, a major trade association representing biotechnology companies and institutions. The goal would be to have more therapeutics that would decrease the severity of the late-stage disease.

The hope is that these drugs might help lower the death toll and the burden on intensive care units in hospitals.

Experts compare the impact of these drugs to that of remdesivir, the most prominent repurposed, antiviral treatment currently available to coronavirus patients. The drug is produced by Gilead Sciences and was originally tested for its effectiveness against other infectious diseases, including the SARS and MERS coronaviruses.

Preliminary clinical trials on the effects of remdesivir in coronavirus patients found that the drug has reduced hospitalization times. More robust clinical trials will be necessary to determine the extent to which the drug helps patients recover.

You have this emergent need for therapeutics, and people are taking everything they have off the shelf, said Dr. Lawrence Blatt, chief executive officer of Aligos Therapeutics, a California-based biotechnology company currently working on a therapeutic candidate for COVID-19. The net result is that most of the therapeutics that are in clinical trials right now are either not going to be effective or will have marginal benefit.

Lets think of it like a lock and key. Each virus has its own lock, Blatt continued. If you took your key from one door and tried to unlock another door, it wouldnt work very well. You have to make a key for that door specifically.

Experimental drug cocktail

A specific key is the gold standard for a coronavirus treatment, and is the current goal of the federal government, which this month placed a $450-million US bet on an experimental drug cocktail that could help infected individuals beat back the coronavirus at earlier stages of infection or even prevent infection in the first place.

We are investing in the candidates that are furthest along so that we could have products by early fall of 2020, a senior administration official working on Operation Warp Speed, the government program to expedite the discovery and production of a coronavirus vaccine, said referring to therapeutics.

While we think it is fair to say that vaccine progress is occurring at warp speed pace, faster than any vaccine has been developed in history, therapeutics are even faster, and we believe well have new options for saving American lives as soon as the early fall, the official told reporters last week.

The drug cocktail, produced by Regeneron, is being made from scratch to address the coronavirus using what is known as monoclonal antibodies protective proteins that have been identified by lab scientists and produced on a large scale to fight off the virus.

It is unclear whether the project will succeed Regeneron has pulled another monoclonal antibody treatment designed to treat rheumatoid arthritis from consideration as a COVID-19 treatment. If the new drug cocktail works, only 300,000 doses will be available by the end of autumn, far short of expected demand.

That would leave doctors and nurses still largely relying on the other repurposed, late-stage treatments, even if Regenerons product ultimately proves successful.

We know that vaccines will take a while, so theres been a lot of discussion about using different kinds of drugs some old drugs, said David Eller, the chairman, co-founder and chief executive officer of Celltex Therapeutics, a Texas-based biotech company conducting Phase II clinical trials for a stem cell treatment of COVID-19. The real issue is, we need something today.

Still, the less ambitious, late-stage treatments that have shown promise could blunt two of the main phenomena identified, up to this point, as fatal to severely ill COVID-19 patients: hyperinflammation and blood clotting.

The lung only fails in so many different ways, and it doesnt matter if its SARS CoV-2, or influenza, or metapneumovirus, said Richard Boucher, director of the Marsico Lung Institute at the University of North Carolina School of Medicine, explaining why he believes some repurposed drugs currently under consideration to treat COVID-19 patients could work. Its going to be therapies that are going to be useful, but are going to be incremental.

Mitigating contagiousness

Last month, Boucher released a major study on how the coronavirus primarily infects the respiratory tract through the nose a critical finding in the search for therapeutics.

Treatments that attempt to mobilize the power of the immune system are proving far more complicated to achieve, Boucher said.

Never miss the latest news from The Spectator, including up-to-date coronavirus coverage, with our email newsletters.

Theres no question that antivirals would be better if you can get them in early, he said. But the second half of the disease, which is immune mediated, is going to be complex. Its a delicate balance. I mean, were on a knifes edge all the time immunologically.

Some scientists are hopeful that the chances of achieving a simpler, early-stage treatment will increase the more they learn about the nature of the coronavirus.

In Miami-Dade County in Florida, Dr. Gustavo Ferrer, president of the Aventura Pulmonary Institute, is working on a therapeutic method recently submitted to the Food and Drug Administration for review that might diminish the viral load of a new infection using a simple nasal spray.

Addressing the potency of the virus early on in the infection would prevent the disease from progressing to a serious stage, and could help mitigate its contagiousness, Ferrer said.

Pharmaceutical companies, he said, are focusing on treating people who have moderate to severe disease.

The great majority of people have mild to moderate symptoms and never get to respiratory failure, Ferrer added. But those people are the ones passing the virus, and were not using anything to control the viral load in that group other than using masks and social distancing.

Blood donations of recovered patients

Five months since the coronavirus outbreak became apparent nationwide, only a handful of treatments have been authorized by the FDA for emergency use on severely ill patients.

The Trump administrations focus remains on monoclonal antibody drugs as well as treatment methods that harness antibodies from the blood donations of recently recovered coronavirus patients convalescent plasma and hyperimmune globulin treatments.

Dr. Janet Woodcock, director of the FDAs Center for Drug Evaluation and Research, is leading the agencys effort to identify therapeutic drugs for the coronavirus. She told reporters last week that the government has been unable to stockpile convalescent plasma because donations are being used up in the current wave of cases across the southern states.

We are in the midst of an outbreak at the moment, said Woodcock. Were doing everything we can to make it available.

Without a strategic supply of convalescent plasma and a massive stockpile of FDA-approved monoclonal antibody drugs to meet demand, the best hope for the fall might well be more modest drugs that can slow down the death rate, experts say.

Over 286 treatments, 192 antiviral drugs and 169 vaccines are currently undergoing clinical trials in the United States, according to a BIO database of coronavirus therapeutic development.

White House press secretary Kayleigh McEnany said last week that therapeutics already in use like remdesivir and convalescent plasma are examples of successes in the U.S. response to the pandemic.

President Donald Trump, at a press conference on Tuesday, said that more therapeutics would hopefully be distributed in the near future.

People are feeling good about our country, Trump said. People are feeling good about therapeutics and possible vaccines.

Report an error

Journalistic Standards

About The Spec

See the article here:
New coronavirus treatments are expected this fall. But how powerful will they be? - TheSpec.com

Adipose Stem Cell Regenerative Medicine in 21st Century …

By Stem Cell Medicine

Adipose tissue is one of the richest sources of stem cells in the body, so it is no coincidence that it is an attractive choice for many therapeutic purposes, including the regeneration and repair of acute and chronically damaged tissues. Another alluring factor is because adipose stem cells are harvested from the patients own body, there are no ethical or moral issues involved in the procedure.

Stem cell therapy is modern medicinesmajor player when it comes to regenerative medicine and tissue engineering. Many medical practitioners also prefer adipose-derived stem cells (ASCs) over other types of stem cells because of the large number available to harvest. The number of ASCs within adipose tissue reaches more than hundreds of times compared with BMSCs (bone marrow stromal/stem stem cells) contained in the same amount of bone marrow.

It is also important to know the characteristics of ASCs for successful clinical application. There are several unique features of ASCs which are known common characteristic of mesenchymal stem cells (MSCs). Mesenchymal stem cells are multipotent stromal cells that can differentiate into a variety of cell types, including: osteoblasts (bone cells), chondrocytes (cartilage cells), and adipocytes (fat cells). Cellular plasticity is one of the most important features of ASCs, the cells also have a special function of immune modulation and immunosuppression. Strong angiogenic potential is another important nature of ASCs. In many reports, ASCs are known not only to be differentiated into osteoblasts, chondrocytes, vascular endothelial cells, but also to be cardiomyocytes and neuronal cells. In conclusion, the new knowledge of ASCs is going to impact on the regenerative medicine

Autologous means that the donor and the recipient are the same person. A small sample of Adipose tissue (fat) is removed from above the love handles (superior Iliac spine) or abdomen under a local anesthetic. The stem cells are then extracted from the removed adipose tissue.

Benefits of ADSC: Stem cells play an integral part in wound healing and regeneration of tissue at the cellular level.

Stem Cells are infused into the bloodstream and injected into localized tissues. The stem cells are attracted to signals from areas of inflammation. Distressed signals trigger stem cells to differentiate. Differentiating cells begin to integrate with target tissues or organs, promoting accelerated healing.

Todays technology allows us to complete the entire procedure on the same day. High Yield: A high-dose of stem cells can be obtained in just a couple of hours. Mesenchymal stem cell yields from peripheral fat are much higher than from bone marrow. Patients receive their own autologous cells, so there is a very low risk of immune rejection. A minimally invasive outpatient procedure makes it easier to harvest from fat than from bone marrow and is more comfortable for patients. Harvested from waste material from a liposuction procedure provides a good opportunity to get rid of unwanted fat.

Adipose-derived mesenchymal stem cells are easier to harvest than bone marrow and can be obtained in much larger quantities. In addition, it is much less painful and involves lower risks.

There is a much shorter time from extraction to the administration of treatment. No culturing or manipulation is needed using our procedure, as opposed to a bone marrow extraction which requires days or weeks to reach the necessary therapeutic threshold.

No, the adipose tissue is extracted from the patients own body so no foreign donors are used. This minimizes the potential for immune rejection. Our procedure is performed completely in-house and administered by our doctors.

Yes because the adipose tissue is removed from ones own body via sterile technique and remains in a controlled environment there are no problems with cell rejection or disease transmission. Once the cells have been harvested they are purified and assessed for quality before being reintroduced back in the patient. Since the stem cells come from the patient there is no possibility for rejection.

Yes! We can now obtain the stem cells from a fat sample. This in-clinic treatment is completed the same day, and there is no need to ship samples to an outside laboratory and wait days for the cells to be returned for an injection on a second visit. This faster process provides increased stem cell counts, without manipulation.

Consultation: Each patient will receive an in-depth consultation prior to their treatment: History, Medications, Patient desires and expected outcomes will be discussed with our highly-qualified doctor.

Adipose stem cells can be used for: Personalized medical treatments; menstrual problems, sleeping problems, stress, neck and shoulder pain, back and lower-back pain, immune system malfunction, constipation, anemia, hormone imbalance, sexual dysfunction, arthritis and connective tissue degeneration, chronic migraine, headache, coronary arteries, blood circulatory system, degeneration of the brain, heart, kidneys, liver and digestive system. Beauty- healthy skin, to make skin smoother, softer, brighter and more youthful. Autologous fat transfer to the face, breasts, or buttocks.

Continued here:
Adipose Stem Cell Regenerative Medicine in 21st Century ...

Cell Separation Market: Global Growth Manufacturers, Regions, Product Types, Major Application Analysis & Forecast to 2025 – CueReport

By Stell Cell Research

Global Cell Separation Market 2020 by Manufacturers, Type and Application, forecast to 2025 is a comprehensive study that delivers market data with characteristics, era, and market chain with analysis and developments and increases. The report offers a prompt point of view on the Cell Separation market, explaining the industry supply, marketplace demand, value, competition, and its analysis of key players with industry forecast from 2020 to 2025. It speaks about the market major leading players, market size over the forecast period from 2020 to 2025.

The Cell Separation market report offers significant information regarding this business vertical. As per the document, the market is estimated to record considerable growth as well as amass notable gains during the estimated timeframe.

Request Sample Copy of this Report @ https://www.cuereport.com/request-sample/22361

The study elaborates the major trends of Cell Separation market while evaluating the growth opportunities, industry size, volume of sales and revenue predictions. The report also provides a detailed assessment of the various segmentations and their respective impact on the overall market outlook. Moreover, it analyzes the effect of COVID-19 pandemic on the growth rate as well as remuneration generation of the market.

Request Sample Copy of this Report @ https://www.cuereport.com/request-sample/22361

As per the regional scope of Cell Separation market:

Other data specified in the Cell Separation market report:

Some of the key questions answered in this report:

What will the Cell Separation market growth rate, growth momentum or acceleration market carries during the forecast period?

Which are the key factors driving the Cell Separation market?

What was the size of the emerging Cell Separation market by value in 2020?

Which region is expected to hold the highest market share in the Cell Separation market?

What will be the size of the emerging Cell Separation market in 2025?

What trends, challenges and barriers will impact the development and sizing of the Global Cell Separation market?

What are sales volume, revenue, and price analysis of top manufacturers of Cell Separation market?

What are the Cell Separation market opportunities and threats faced by the vendors in the global Cell Separation Industry?

Request Customization on This Report @ https://www.cuereport.com/request-for-customization/22361

Follow this link:
Cell Separation Market: Global Growth Manufacturers, Regions, Product Types, Major Application Analysis & Forecast to 2025 - CueReport

Cytomegalovirus Treatment Market : Opportunities and Forecast Assessment, 20192026 – 3rd Watch News

By Stem Cell Treatment

The Cytomegalovirus Treatment Market research report added by Market Study Report, LLC, provides a succinct analysis on the recent market trends. In addition, the report offers a thorough abstract on the statistics, market estimates and revenue forecasts, which further highlights its position in the industry, in tandem with the growth strategies adopted by leading industry players.

The Cytomegalovirus Treatment market study is a well-researched report encompassing a detailed analysis of this industry with respect to certain parameters such as the product capacity as well as the overall market remuneration. The report enumerates details about production and consumption patterns in the business as well, in addition to the current scenario of the Cytomegalovirus Treatment market and the trends that will prevail in this industry.

Request Sample Report @https://www.mrrse.com/sample/19063?source=atm

What pointers are covered in the Cytomegalovirus Treatment market research study?

The Cytomegalovirus Treatment market report Elucidated with regards to the regional landscape of the industry:

The geographical reach of the Cytomegalovirus Treatment market has been meticulously segmented into United States, China, Europe, Japan, Southeast Asia & India, according to the report.

The research enumerates the consumption market share of every region in minute detail, in conjunction with the production market share and revenue.

Also, the report is inclusive of the growth rate that each region is projected to register over the estimated period.

The Cytomegalovirus Treatment market report Elucidated with regards to the competitive landscape of the industry:

Competitive Assessment

This chapter includes a comprehensive list of all the leading manufacturers in the Cytomegalovirus treatment market, along with detailed information about each company, including company overview, revenue share, strategic overview, and recent company developments. Market players featured in the report include Merck & Co. Inc, Mylan N.V., Chimerix, Inc., Thermo Fisher Scientific, Abbott, Becton, Dickinson and Company, Johnson & Johnson, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, Pfizer and among others

Chapter 15 Global Cytomegalovirus Treatment Market Analysis 2013-2017 and Opportunity Assessment 2018-2028 by Region

This section highlights Cytomegalovirus treatment in the overall global market by value (US$ Mn) forecast and analysis, by region such as North America, Latin America, Western Europe, Eastern Europe and Asia Pacific Including Japan, China and MEA.

Chapter 16 Global Cytomegalovirus Treatment Market Analysis 2013-2017 and Opportunity Assessment 2018-2028 by Drug Type

Based on drug type market analysis, the Cytomegalovirus treatment market is segmented into Ganciclovir, valganciclovir, Foscarnet, Cidofovir and other.

Chapter 17 Global Cytomegalovirus Treatment Market Analysis 2013-2017 and Opportunity Assessment 2018-2028 by Application

Based on Application, the Cytomegalovirus treatment market is segmented into Stem Cell Transplantation, Organ Transplantation, Congenital CMV infection and others.

Chapter 18 Global Cytomegalovirus Treatment Market Analysis 2013-2017 and Opportunity Assessment 2018-2028 by Distribution Channel

Based on distribution channel, the Cytomegalovirus treatment market is segmented into hospital pharmacies, retail pharmacies, drugstores, and e-Commerce.

Chapter 19 Global Cytomegalovirus Treatment Market Analysis 2013-2017 and Opportunity Assessment 2018-2028

This section highlights the overall global market value (US$ Mn) forecast and analysis of the Cytomegalovirus treatment market, with detailed incremental opportunity and absolute opportunity.

Chapter 20 Assumptions and Acronyms Used

This section consists of a glossary of the assumptions and acronyms used in the Cytomegalovirus treatment market report.

Chapter 21 Research Methodology

This chapter helps readers understand the research methodology that is followed to obtain various conclusions, important qualitative information, and quantitative information about the Cytomegalovirus treatment market.

Request For Discount On This Report @ https://www.mrrse.com/checkdiscount/19063?source=atm

Exclusive details pertaining to the contribution that every firm has made to the industry have been outlined in the study. Not to mention, a brief gist of the company description has been provided as well.

Substantial information subject to the production patterns of each firm and the area that is catered to, has been elucidated.

The valuation that each company holds, in tandem with the description as well as substantial specifications of the manufactured products have been enumerated in the study as well.

The Cytomegalovirus Treatment market research study conscientiously mentions a separate section that enumerates details with regards to major parameters like the price fads of key raw material and industrial chain analysis, not to mention, details about the suppliers of the raw material. That said, it is pivotal to mention that the Cytomegalovirus Treatment market report also expounds an analysis of the industry distribution chain, further advancing on aspects such as important distributors and the customer pool.

The Cytomegalovirus Treatment market report enumerates information about the industry in terms of market share, market size, revenue forecasts, and regional outlook. The report further illustrates competitive insights of key players in the business vertical followed by an overview of their diverse portfolios and growth strategies.

Buy This Report @ https://www.mrrse.com/checkout/19063?source=atm

Some of the Major Highlights of TOC covers:

Read the rest here:
Cytomegalovirus Treatment Market : Opportunities and Forecast Assessment, 20192026 - 3rd Watch News

→←